Inhibitors of anaplastic lymphoma kinase: a patent review

Bibliography

• Rottgers S, Gombert M, Teigler-Schlegel A, ALK fusion genes in children with atypical myeloproliferative disease. Leukemia 2010;24:1197-200
   PubMed Web of Science ®Google Scholar
• Palmer RH, Vernersson E, Grabbe C, Anaplastic lymphoma kinase: signaling in development and disease. Biochem J 2009;420(3):345-61
   Google Scholar
• Chiarle R, Voena C, Ambrogio C, The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer 2008;8(1):11-23
   Google Scholar
• Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99(12):2349-55
   Google Scholar
• Mosse YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009;15(18):5609-14
   PubMed Web of Science ®Google Scholar
• Lee CC, Jia Y, Li N, Crystal structure of the anaplastic lymphoma kinase (ALK) catalytic domain Biochem J 2010;430(3):425-37
   Google Scholar
• Bossi RT, Saccardo MB, Ardini E, Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010;49(32):6813-25
   Google Scholar
• Cheng M, Ott GR. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anticancer Agents Med Chem 2010;10(3):236-49
   Google Scholar
• Webb TR, Slavish J, George RE, Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9(3):331-56
   Google Scholar
• Chiarle R, Martinengo C, Mastini C, The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008;14(6):676-80
   Google Scholar
• Mastini C, Martinengo C, Inghirami G, Anaplastic lymphoma kinase: an oncogene for tumor vaccination. J Mol Med 2009;87(7):669-77
   Google Scholar
• Chiarle R, Inghirami G, Forni G. Anaplastic lymphoma kinase (alk) as oncoantigen for lymphoma vaccination. EP2042191; 2009
   Google Scholar
• Inghirami G, Chiarle R. Alk protein tyrosine kinase fused with nucleophosmin and siRNA against ALK gene expression for treating lymphoma. WO2004096142; 2004
   Google Scholar
• Esbatech. Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK. WO2007124610; 2007
   Google Scholar
• Esbatech. Anti-anaplastic lymphoma kinase antibodies suitable for treating metastatic cancers or tumors. WO2008131575; 2008
   Google Scholar
• Medimmune. Anti-anaplstic lymphoma kinase antibodies, antagonists and agonists for diagnosis and treatment of cancer. WO2007059300; 2007
   Google Scholar
• Phase 2, Open-Label Single Arm Study of the efficacy and safety of PF-02341066 in patients with non-small cell lung cancer harboring A translocation or inversion event involving the anaplastic lymphoma kinase (ALK) Gene, NCT00932451. Available from: www.clinicaltrials.gov, 2010
   Google Scholar
• Phase 3, Randomized, Open-Label Study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (Pemetrexed Or Docetaxel) in patients with non-small lung cancer harboring A translocation or inversion event involving the anaplastic lymphoma kinase (ALK) Gene Locus, NCT00932893. Available from: www.clinicaltrials.gov, 2010
   Google Scholar
• Phase 1B Open-Label Study of the safety and clinical activity of crizotinib (pf-02341066) in tumors with genetic events involving the anaplastic lymphoma (LKA) Gene Locus, NCT01121588. Available from: www.clinicaltrials.gov, 2010
   Google Scholar
• Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study of pf-02341066, a c-met/hgfr selective tyrosine kinase inhibitor, administered orally to patients with advanced cancer, NCT00585195. Available from: www.clinicaltrials.gov, 2010
   Google Scholar
• A Phase I/II Study of PF-02341066, an oral small molecule inhibitor of anaplastic lymphoma kinase (alk) and c-met, in children with relapsed/refractory solid tumors, primary cns tumors, and anaplastic large cell lymphoma, NCT00939770. Available from: www.clinicaltrials.gov, 2010
   Google Scholar
• Christensen JG, Zou HY, Arango ME, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12,Pt. 1):3314-22
   PubMed Web of Science ®Google Scholar
• Sugen. Preparation of aminoheteroaryl compounds as protein kinase inhibitors. PCT Int Appl WO2004076412; 2004
   Google Scholar
• Pfizer. Preparation of aminoheteroaryl compounds as c-Met tyrosine kinase inhibitors. PCT Int Appl WO2006021886; 2006
   Google Scholar
• Xcovery, Inc. Substituted pyridazine carboxamide compounds as kinase inhibitor compounds. WO2009154769; 2009
   Google Scholar
• Cephalon, Inc. Preparation of pyridopyrazine derivatives as ALK and c-Met inhibitors. WO2007130468; 2007
   Google Scholar
• Milkiewicz KL, Weinberg LR, Albom MS, Synthesis and structure–activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem 2010;18(12):4351-62
   Google Scholar
• Ariad. Pyrazinopyrazine derivatives as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2010056311; 2010
   Google Scholar
• Ariad. Azaindole derivatives as kinase inhibitors. WO2010068292; 2010
   Google Scholar
• OSI pharmaceuticals Substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrazines as inhibitors of c-Met and RON tyrosine kinase receptor and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2010059771; 2010
   Google Scholar
• To the best of our knowledge, the earliest patents in the DAP class targeting ATP pockets were ATP-ase inhibitors (a) SmithKline Beecham. Preparation of diaminopyrimidines as gastric acid secretion inhibitors. WO9118887; 1991. The earliest kinase specific patent:(b) Celltech Therapeutics Limited. Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors. WO9719065; 1997
   Google Scholar
• Novartis. Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. WO2004080980; 2004
   Google Scholar
• Galkin AV, Melnick JS, Kim S, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104(1):270-5
   Google Scholar
• Novartis. Preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of proliferative disorders. WO2005026130; 2005
   Google Scholar
• Novartis. Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. WO2005016894; 2005
   Google Scholar
• Novartis. Preparation of 2,4-di[(hetero)arylamino]pyrimidine derivatives as ZAP-70 and/or SYK inhibitors. WO2005026158; 2005
   Google Scholar
• Novartis. Preparation of pyrimidine compounds as FAK and/or ALK inhibitors. WO2006021457; 2006
   Google Scholar
• Novartis. Preparation of N,N′-diarylpyrimidinediamine for use as protein kinase inhibitors. WO2008073687; 2008
   Google Scholar
• Novartis. Preparation of pyrimidine compounds as IGF-1 receptor and anaplastic lymphoma kinase inhibitors to treat proliferative disorders. WO2009158431; 2009
   Google Scholar
• Novartis. Pyrimidine derivatives as IGF-1R and ALK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2009032668; 2009
   Google Scholar
• Novartis. Preparation of substituted 2-(phenylamino)pyrimidin-4-amine as IGF-1 receptor and anaplastic lymphoma kinase inhibitors for treating proliferative disorders. WO2010002655; 2010
   Google Scholar
• Cephalon, Inc. Preparation of fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors. WO2008051547; 2008
   Google Scholar
• Ott GR, Tripathy R, Cheng M, Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumour activity. ACS Med Chem Lett 2010; DOI: 10.1021/ml100158s
   Google Scholar
• Quail MR, Lu L, Ghose AK, In vitro Activity and in vivo Efficacy of a Benzazepinone ALK Inhibitor in EML4-ALK Positive and Negative Non-Small Cell Lung Cancer Cells (Abstract 3735). Proc Am Assoc Cancer Res 2009
   Google Scholar
• Lu L, Quail MR, Jones M, In vitro activity and in vivo efficacy of a Benzazepinone ALk inhbitor on human neuroblastoma-derived cell lines(Abstract 3736). Proc Am Assoc Cancer Res 2009
   Google Scholar
• Ariad. Preparation of phosphorus derivatives as kinase inhibitors. WO2009143389; 2009
   Google Scholar
• Rivera VM, Anjum R, Wang F, Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (Abstract 3623) (ALK). Proc Am Assoc Cancer Res 2010
   Google Scholar
• Zhang S, Wang F, Keats J, AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (Abstract LB-298) (PF1066). Proc Am Assoc Cancer Res 2010
   Google Scholar
• Novartis. Preparation of 2-(Het)arylamino-6-aminopyridine derivatives and fused forms thereof as kinase inhibitors for treating hyperproliferative and angiogenesis disorders WO2009032703; 2009
   Google Scholar
• Novartis. Preparation of triazine and pyrimidine derivatives as kinase inhibitors. WO2009126514; 2009
   Google Scholar
• Novartis. Preparation of pyrimidine derivatives as protein kinase inhibitors for treating proliferative disorders, immune disorders, and infections. WO2009126515; 2009
   Google Scholar
• GlaxoSmithKline. Preparation of 2-[[2-(phenylamino)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]benzamide derivatives as inhibitors of IGF-1R and IR receptor tyrosine kinase and ALK kinase for treating cancer WO2009020990; 2009
   Google Scholar
• GlaxoSmithKline. Preparation of pyrrolopyrimidine derivatives for use as IGF-1R inhibitors. WO2010045451; 2010
   Google Scholar
• Chamberlain SD, Redman AM, Wilson JW, Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg Med Chem Lett 2009;19(2):360-4
   Google Scholar
• Chamberlain SD, Redman AM, Patnaik S, Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett 2009;19(2):373-7
   Google Scholar
• Chamberlain SD, Wilson JW, Deanda F, Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg Med Chem Lett 2009;19(2):469-73
   Google Scholar
• Sabbatini P, Korenchuk S, Rowand JL, GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 2009;8(10):2811-20
   Google Scholar
• Astellas Pharma. Preparation of di(arylamino)aryl derivatives as inhibitors of kinase activity of EML4-ALK fusion protein and EGFR variant protein. WO2009008371; 2009
   Google Scholar
• Astellas Pharma. Di(arylamino)aryl Compound. US2010/0099658; 2010
   Google Scholar
• Astellas Pharma. Di(arylamino)aryl Compound. US2010/0099658; 2010
   Google Scholar
• Janssen Pharmaceutica. Preparation of cyclic peptides and analogs thereof containing pyrimidines for treating hyperproliferative disorders. PCT Int Appl WO2006061415; 2006
   Google Scholar
• Incyte. Macrocyclic compounds as kinase inhibitors and their preparation, pharmaceutical compositions and their use in the treatment of JAK/ALK-associated diseases. WO2009132202; 2009
   Google Scholar
• Li R, Xue L, Zhu T, Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase. J Med Chem 2006;49(3):1006-15
   Google Scholar
• Chembridge and St. Jude's Children's Research hospital. Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders. WO2008021369; 2008
   Google Scholar
• Chembridge and St. Jude's Children's Research hospital Preparation of imidazo[4,5-f]isoindole derivatives as tyrosine kinase inhibitors. WO2009117097; 2009
   Google Scholar
• Wittman M, Carboni J, Attar R, Discovery of a 1H-Benzoimidazol-2-yl-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor i receptor kinase with in vivo antitumor activity. J Med Chem 2005;48(18):5639-43
   Google Scholar
• Velaparthi U, Wittman M, Liu P, Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem 2008;51(19):5897-900
   Google Scholar
• AstraZeneca. Preparation of tricyclyl 2,4-diamino-1,3,5-triazine derivatives as JAK inhibitors. WO2009150462; 2009
   Google Scholar
• Bristol-Myers Squibb. Triazine derivatives as tyrosine kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2009015254; 2009
   Google Scholar
• Exelixis. Preparation of pyrazolo[3,4-c]isoquinoline derivatives as anaplastic lymphoma kinase modulators. WO2005009389; 2005
   Google Scholar
• Leahy JW, Lewis GL, Nuss JM, Preparation of thiazoles and analogs as anaplastic lymphoma kinase modulators. WO2005097765; 2007
   Google Scholar
• Universita Degli Studi di Milan, Universite de Geneve, and Universite Claue Bernard Lyon. Preparation of heterocyclylthiazolylbenzene derivatives and analogs for use as antiproliferative agents. Universita Degli Studi di Milano – Bicocca, Italy; Universite de Geneve; Universite Claude Bernard Lyon WO2009121535; 2009
   Google Scholar
• Universita Degli Studi di Milan, Universite de Geneve, and Universite Claue Bernard Lyon. Preparation of 9H-pyrido[2,3-b]indoles as inhibitors of oncogenic protein kinases useful in the treatment of cancer. WO2010025872; 2010
   Google Scholar
• Nerviano Medical Sciences. Indazole derivatives as kinase inhibitors for the treatment of cancer and their preparation. WO2008074749; 2008
   Google Scholar
• Nerviano Medical Sciences. Preparation of substituted indazole derivatives for use as kinase inhibitors WO2009013126; 2009
   Google Scholar
• Nerviano Medical Sciences. Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs for the treatment of cancer and their preparation. WO2009138440; 2009
   Google Scholar
• Nerviano Medical Sciences. Preparation of substituted indazole derivatives active as kinase inhibitors for treating cancer, cell proliferative disorders, and other diseases. WO2010069966; 2010
   Google Scholar
• Aridini E, Menichincheri M, De Ponti C, A highly potent and selective and orally available ALK inhibitor with demonstrated anti-tumor efficacy in ALK dependent lymphoma and non small cell lung cancer models (Abstract 3737). Proc Am Assoc Cancer Res 2009
   Google Scholar
• Novartis. Preparation of imidazoquinoline derivatives as protein kinase inhibitors. WO2005054237; 2005
   Google Scholar
• Novartis. Preparation of substituted fused naphthyridines as protein kinase inhibitors. WO2007134259; 2007
   Google Scholar
• Cephalon, Inc. Preparation of heterocyclylpyrazolinones as protein kinase inhibitors. WO2001032653; 2001
   Google Scholar
• McHugh RJ, Tripathy R, Angeles T, Design and synthesis of pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors. Abstracts of Papers, 235th ACS National Meeting; New Orleans, LA, United States; 2008
   Google Scholar
• Quail MR, Lu L, Wan W, PI3K/Akt/mTOR activity is a major determinant for the sensitivity of NPM-ALK (+) Anaplastic large cell lymphoma cells to ALK inhibition (Abstract # 2503). Proc Am Assoc Cancer Res 2010
   Google Scholar
• Lin E, Li L, Guan Y, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7(9):1466-76
   Google Scholar